Intensity Therapeutics, Inc. (INTS) has disclosed a new risk, in the Regulation category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Changes in U.S. tariff and import/export regulations could materially disrupt Intensity Therapeutics, Inc.’s supply chains, increase costs for key inputs, and complicate cross‑border clinical and commercial operations. Heightened uncertainty in global trade policy and potential contractions in international economic activity may also pressure its financial condition, operating results, and common stock valuation.
The average INTS stock price target is $30.00, implying 397.51% upside potential.
To learn more about Intensity Therapeutics, Inc.’s risk factors, click here.